GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France
Portfolio Pulse from
GenSight Biologics has submitted an updated regulatory file for its LUMEVOQ® gene therapy to the French agency ANSM, aiming to restart its Early Access Program in France.
November 13, 2024 | 7:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GenSight Biologics has submitted a regulatory dossier for LUMEVOQ® to the French ANSM, aiming to restart its Early Access Program in France.
The submission of the LUMEVOQ® dossier to ANSM is a significant regulatory step for GenSight Biologics, indicating progress towards restarting the Early Access Program in France. This could positively impact the company's stock as it shows advancement in their product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90